SLU-PP-332: an exercise mimetic with no human data whatsoever
This page exists to describe a compound accurately rather than to help anyone use it. Every published result comes from rodents, no human has been dosed in a study, and there is no dose to report. That is the whole picture, and it is worth understanding as an example of how early a compound can be while still circulating.
Regulatory status. The app’s reference records this compound’s status as “Research”, reproduced here rather than summarised. It means no regulator has reviewed a manufacturer’s evidence for identity, purity, potency or safety in people for this compound, so nothing below is a marketing claim about a product you can buy.
Purity, identity and concentration are therefore unverified by anyone but whoever made the vial. The storage rule in the fact box below is general practice for this formulation rather than a specification for a particular product: General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
This page names no vendor, no clinic and no testing service, and there is no discount code anywhere on this site — the moment a page like this recommends where to buy, it stops being information.
- Also known as
- SLU-PP-332, Exercise Mimetic
- Class
- Metabolic research compound
- Regulatory status
- Research
- Storage
- Room temperature and dry, in the original container with whatever desiccant came in it, out of light.
- Once opened
- Unchanged once opened, as long as it stays dry.
- What ruins it
- Humidity is the real enemy — a bathroom cabinet is the worst place in the house for these.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
What a pan-ERR agonist does
Established clinical use The estrogen-related receptors — ERRα, ERRβ and ERRγ — are nuclear receptors that, despite the name, are not activated by oestrogen. They regulate mitochondrial biogenesis, oxidative metabolism and the expression programme that endurance training switches on in skeletal muscle. That biology is well established and independent of any particular drug.
SLU-PP-332 is a synthetic agonist at all three. The reasoning behind it is direct: if endurance exercise produces its metabolic adaptations partly through this pathway, an agonist might reproduce some of them. The term “exercise mimetic” describes that intent, and it is an intent rather than a demonstrated result.
Animal-only or theoretical In published mouse work the compound increased fatty-acid oxidation, extended running capacity on a treadmill and reduced fat mass without a change in food intake or in voluntary activity. Those are real, reported findings in mice. Half-life in the rodent data is short, on the order of a couple of hours, which is one of several reasons a human schedule cannot be inferred from them.
Why there is no dose on this page
Animal-only or theoretical The app’s own entry records no established human dose, and this page does not invent one. No phase I study has been published, so nothing is known about human pharmacokinetics, tolerated exposure, or which of the rodent effects translate. Interspecies scaling from a mouse dose is a method for designing a first-in-human study, not for choosing what to take.
The gap matters more here than it would for a compound with a long clinical history in a different indication. Nuclear receptor agonists act by changing gene expression across many tissues, and the receptors here are expressed in heart, kidney and liver as well as in skeletal muscle. A compound that shifts the oxidative programme everywhere is not obviously benign because the muscle result looked good, and cardiac effects in particular are the sort of thing a phase I study exists to detect.
It is also worth naming what a research chemical is. Material sold under this name has not been through any pharmaceutical quality process, identity and purity rest on the seller’s own certificate, and there is no regulator between that certificate and the buyer. This site names no vendor.
The comparison that actually matters
Endurance exercise is the intervention this compound is named after, and it has outcome data no drug in this class approaches: reduced cardiovascular and all-cause mortality across large cohorts and randomised trials of structured training. Whatever an exercise mimetic eventually turns out to do, it starts from a long way behind that.
Off-label or community practice For fat loss specifically, there are compounds with human trial evidence and approvals — the GLP-1 receptor agonists are the obvious point of contrast, with cardiovascular outcome data behind them. Someone reaching for a preclinical research compound for body composition is choosing the option with the least evidence available for that goal.
There is no monitoring protocol to offer, because nobody has established what to monitor or what a concerning value would be. The app records exactly that, and it is the correct entry. Anyone weighing a compound at this stage should be having that conversation with a doctor who can see the rest of their picture.
The dosing rows the app records
Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.
| Label | Amount | Route and frequency | Duration recorded |
|---|---|---|---|
| Research Only | No established human dose | Investigational | No human protocols exist |
What the app monitors alongside it
The panel below is the app’s own monitoring note for SLU-PP-332, verbatim. None of the analytes it names has a page here yet.
- Monitoring panel
- No established monitoring; Experimental — caution advised
Drawbacks and risks the app records
From the app’s own entry. Read the last item as the summary rather than an afterthought.
- No human studies whatsoever
- Entirely preclinical / experimental
- Long-term safety completely unknown
- No established human dosing
- Research chemical — purity varies
- Not a substitute for actual exercise
Questions people actually ask
Has any person taken this in a study?
No published human study exists. Everything reported comes from rodent work, and no phase I data has appeared.
What dose do people use?
This page does not carry one, because there is no established human dose to carry. The app records the same. A dose scaled from mouse data is a hypothesis for a trial, not a protocol.
Does it replace cardio?
No. The compound reproduced some metabolic markers of endurance training in mice. Endurance exercise has mortality and cardiovascular outcome data behind it that nothing in this class approaches.
What should be monitored?
Nothing has been established, which is itself the answer. There are no reference values, no known signal to watch, and no way to tell an expected effect from an adverse one.
Where the load-bearing numbers come from
Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.
- ERR receptors regulate oxidative metabolism
- Established nuclear receptor biology, independent of this compound
- Increased fat oxidation and running capacity
- Rodent studies; no human replication
- Fat loss without change in intake or activity
- Reported in mouse models only
- Human dose and safety
- No published phase I data; app.html records no established dose
- Endurance exercise outcomes
- Large cohort and randomised training data; the comparison the name invites
If you are tracking anything at this stage, track it carefully. TherapyLog keeps the record, whatever the compound turns out to be worth.
Save this dose to your log